Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986213 · 2 trials · 4 indications
The number of LAG-3 Positive (\>=1%) participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized LAG-3 positive (\>=1%) participants in each arm; recorded between randomization date and the date of objectively documented progression \[per RECISIT 1.1\], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions
The number of LAG-3 Positive (\>=1%) participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized LAG-3 positive (\>=1%) participants in each arm; recorded between randomization date and the date of objectively documented progression \[per RECISIT 1.1\], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions Progression=At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study and the sum must also demonstrate an absolute increase of at least 5 mm.
| Arm | Type | Description |
|---|---|---|
| BMS-986213 + investigator's choice chemotherapy | EXPERIMENTAL | BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX |
| Nivolumab + investigator's choice chemotherapy | EXPERIMENTAL | Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX |
| Cohort A: BMS-986213 Fixed Dose Combination | EXPERIMENTAL | - |
| Cohort B: BMS-986213 Fixed Dose Combination | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986213 | BIOLOGICAL | Relatlimab + Nivolumab specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
| XELOX | DRUG | Oxaliplatin + capecitabine |
| FOLFOX | DRUG | Oxaliplatin + leucovorin + fluorouracil |
| SOX | DRUG | Oxaliplatin + tegafur/gimeracil/oteracil potassium |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Histologically- or cytologically-confirmed diagnosis of unresectable and eithe...
Top 20 of 45 competitors
BMS-986213 is an investigational small molecule being studied for the treatment of gastric cancer and advanced solid tumors. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
BMS-986213 is a small molecule, but its specific molecular target has not been disclosed. It is being investigated in combination with chemotherapy for gastric or gastroesophageal junction cancers and in a fixed-dose combination with relatlimab and nivolumab for advanced solid tumors.
BMS-986213 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology indications.
BMS-986213 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in early-stage trials to assess its safety, tolerability, and preliminary efficacy.
BMS-986213 has been studied in two completed clinical trials. NCT03662659 was a Phase 2 study of immunotherapy combinations with chemotherapy in gastric or gastroesophageal junction cancers, enrolling 274 participants. NCT05134948 was a Phase 1 study of relatlimab and nivolumab fixed-dose combination in Chinese participants with advanced solid tumors, enrolling 24 participants.
BMS-986213 is not the same as relatlimab and nivolumab. It is a separate investigational small molecule. However, it has been studied in combination with relatlimab and nivolumab as a fixed-dose combination in a clinical trial for advanced solid tumors.